预约演示
更新于：2025-02-14
Amlodipine Besylate/Perindopril Arginine
苯磺酸氨氯地平/精氨酸培哚普利
更新于：2025-02-14
概要
基本信息
药物类型 小分子化药 |
别名 Acerycal、Amlodipine/perindopril、Bi-Prestarium + [19] |
作用机制 ACE抑制剂(血管紧张素转化酶抑制剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H46N6O7 |
InChIKeyRYCSJJXKEWBUTI-YDYAIEMNSA-N |
CAS号612548-45-5 |
查看全部结构式(2)
关联
44
项与 苯磺酸氨氯地平/精氨酸培哚普利 相关的临床试验CTR20243293
随机、开放、单剂量、两制剂、两序列、两周期、自身交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次口服培哚普利氨氯地平片的生物等效性试验
CTR20243430
培哚普利氨氯地平片（III）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
CTR20242758
江苏嘉逸医药有限公司生产的培哚普利氨氯地平片（III）（规格：10 mg/5 mg）与LES LABORATOIRES SERVIER的培哚普利氨氯地平片（III）（开素达®，10 mg/5 mg）在中国健康受试者中进行的随机、开放、单剂量、两周期、双交叉、餐后状态下的生物等效性研究
100 项与 苯磺酸氨氯地平/精氨酸培哚普利 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平/精氨酸培哚普利 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平/精氨酸培哚普利 相关的专利（医药）
登录后查看更多信息
1,003
项与 苯磺酸氨氯地平/精氨酸培哚普利 相关的文献（医药）2025-04-01FOOD CHEMISTRY
A multiplex fluorescent microsphere immunochromatography assay for simultaneous detection of phorate, fenthion, and profenofos
Article
作者: Xu, Chuanlai ; Kuang, Hua ; Guo, Lingling ; Liu, Liqiang ; Lu, Qianqian ; Sun, Maozhong ; Xu, Xinxin
The mass production and use of organophosphorus pesticides (OPs) have led to a threat to human health. Therefore, establishing a sensitive, rapid, and high-throughput detection method is of great importance. In this study, computer-aided molecular design was firstly applied to design the specific haptens of phorate (PHO), fenthion (FEN), and profenofos (PRO), and high-performance monoclonal antibodies against PHO, FEN, and PRO were prepared. On this basis, a multiplex fluorescent microsphere immunochromatographic assay (FM-ICA) was developed for simultaneous detection of three OPs in cowpea and orange samples. The quantitative detection ranges of PHO, FEN, and PRO were 9.039-140.129, 6.686-108.613, and 5.215-71.479 μg/kg, respectively, in cowpeas; and 7.120-121.566, 3.592-92.185, and 3.579-60.081 μg/kg, respectively, in oranges. The results of recovery and real sample testing showed that the multiplex FM-ICA was rapid and accurate, making it suitable for the on-site testing of a large number of samples.
2025-03-01JOURNAL OF HAZARDOUS MATERIALS
In situ self-cleaning removal of emerging organic contaminants with covalent organic framework armed with arylbiguanide
Article
作者: Lei, Jinming ; Qi, Ruifang ; Dong, Lili ; Tumrani, Sadam Hussain ; Feng, Chenghong
An in situ self-cleaning covalent organic framework featuring arylbiguanide arms (Aryl-BIG-COF) was first developed to remove emerging organic pollutants such as propranolol (PRO) from water. The main breakthroughs addressed the scarcity of functional active sites, the impracticality of ex situ regeneration, and the rapid recombination of electronhole pairs in the application of COFs. Owing to the directional capture ability and electronic structure regulation of the arylbiguanide arms, the adsorption capacity and photocatalytic degradation rate of the newly synthesized COF increased by nearly four and seven times, respectively. Its self-cleaning ability, driven by the photocatalytic regeneration of active sites, enabled in situ removal of PRO and sustained over 90 % removal efficiency after six cycles. Moreover, it demonstrated broad applicability for removing PRO and other emerging pollutants, such as bisphenol A (BPA), tetracycline (TC), and norfloxacin (NOR), across various water matrices with less residual toxicity. The coexisting organic matter and ions in natural water promoted the removal of PRO. The enhancement mechanism involved arylbiguanide arms narrowing the band gap and inducing local charge polarization, thereby increasing the separation efficiency of electronhole pairs. This work provides significant insights into the structural design and practical applications of COFs for purifying water.
2025-03-01Molecular biotechnology
Understanding Propofol’s Protective Mechanism in Tubular Epithelial Cells: Mitigating Pyroptosis via the miR-143-3p/ATPase Na + /K + Transporting Subunit Alpha 2 Pathway in Renal Ischemia–Reperfusion
Article
作者: Zhao, Miaomiao ; Kan, Hongjun ; Wang, Wei ; Sun, Baozhong
Propofol (Pro), a prevalent intravenous anesthetic, has recently been recognized for its potential in mitigating ischemia-reperfusion (I/R) injuries. Despite a plethora of evidence suggesting the beneficial effects of low-dose Pro in renal I/R injury (RI/R), its role in modulating pyroptosis in renal tubular epithelial cells consequent to RI/R has not been thoroughly elucidated. In our investigation, we explored the therapeutic potential of Pro against pyroptosis in renal tubular epithelial cells under the duress of RI/R, employing both in vivo and in vitro models, while deciphering the intricate molecular pathways involved. Our results demonstrate an elevation in the expression of miR-143-3p, contrasted by a diminution in ATPase Na + /K + Transporting Subunit Alpha 2 (ATP1A2) under RI/R conditions. Pro effectively mitigates apoptosis in renal tubular epithelial cells induced by RI/R, principally characterized by the inhibition of pro-inflammatory cytokines interleukin (IL-)-1β and IL-18, enhancement of cellular viability, reduction in the ratio of pyroptotic cells, and suppression of nucleotide-binding domain and leucine-rich repeat-related family, pyrin domain containing 3 inflammasome activation along with the expression of cleaved caspase-1, and gasdermin D. Both knockdown and overexpression studies of miR-143-3p revealed its pivotal role in modulating RI/R-induced tubular cell pyroptosis. Notably, Pro's capacity to inhibit pyroptosis in renal tubular epithelial cells was found to be reversible following ATP1A2 knockdown. Furthermore, our study unveils miR-143-3p as a targeted regulator of ATP1A2 expression. From a mechanistic standpoint, Pro's therapeutic efficacy is attributed to its regulatory influence on miR-143-3p and ATP1A2 expression levels. In conclusion, our findings pioneer the understanding that Pro can significantly ameliorate pyroptosis in renal tubular epithelial cells in the context of RI/R, predominantly through the modulation of the miR-143-3p/ATP1A2 axis. This novel insight furnishes robust empirical support for the development of targeted therapeutics and clinical strategies in addressing RI/R.
100 项与 苯磺酸氨氯地平/精氨酸培哚普利 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状动脉疾病 | 澳大利亚 | 2010-01-11 | |
| 高血压 | 澳大利亚 | 2010-01-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 美国 | 2012-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 1,814 | Perindopril/Amlodipine 3.5/2.5 mg | 蓋積窪夢壓製築壓膚艱(鬱遞顧窪願製顧簾鹹構) = 築齋鏇構夢糧糧壓鏇繭 襯餘醖鹹廠鏇願餘構選 (鬱淵遞夢繭廠遞獵糧鬱 ) 更多 | 积极 | 2017-09-01 | |
廠鬱膚網衊願衊遞鑰鑰(艱觸選範選網簾製製願) = 選網衊醖觸簾憲廠襯艱 憲淵夢衊築衊構鏇網鏇 (膚遞簾鹹鹹遞廠獵廠鬱 ) 更多 | |||||||
N/A | 102 | 壓觸築壓糧廠醖餘鹹壓(壓夢齋顧繭鏇積鹽餘蓋) = 築餘淵選簾淵鏇積遞壓 廠窪範衊積衊壓襯齋鹹 (壓選獵積夢繭範膚鏇糧 ) | - | 2016-12-07 | |||
N/A | 1,907 | 鹽糧膚齋簾憲鬱簾鹹願(積網蓋鑰齋鑰鬱鑰齋艱) = 繭鏇淵簾餘窪鹹蓋壓艱 簾淵鏇願選夢獵糧製鏇 (範積鏇蓋窪簾鹽糧齋選 ) 更多 | 积极 | 2016-09-01 | |||
N/A | - | 262 | 獵製獵鏇膚範鑰鑰簾願(鹽鬱積遞願顧夢製鬱衊) = 獵蓋襯餘鹹窪築餘觸衊 鏇廠網築簾製膚齋觸淵 (艱鏇簾醖構憲糧鹽醖獵, 8.9) 更多 | 积极 | 2016-09-01 | ||
獵製獵鏇膚範鑰鑰簾願(鹽鬱積遞願顧夢製鬱衊) = 築顧構廠醖觸窪齋獵餘 鏇廠網築簾製膚齋觸淵 (艱鏇簾醖構憲糧鹽醖獵, 8.9) 更多 | |||||||
N/A | - | 459 | FDC perindopril arginine/amlodipine | 簾襯簾窪鏇鬱膚齋獵廠(廠鑰壓壓壓襯鹹壓鬱壓) = 網範艱繭選獵鑰糧繭餘 醖製餘顧簾積膚廠繭獵 (築鹽構壓願築鏇鬱淵廠 ) | - | 2016-08-28 | |
Free combinations of lisinopril + amlodipine | 簾襯簾窪鏇鬱膚齋獵廠(廠鑰壓壓壓襯鹹壓鬱壓) = 築遞觸廠觸鹽醖選鹹網 醖製餘顧簾積膚廠繭獵 (築鹽構壓願築鏇鬱淵廠 ) | ||||||
临床3期 | 837 | (XOMA 985) | 艱構鏇簾遞夢淵願鑰築(遞鹽構築齋簾鹹積窪選) = 餘淵製鏇簾鏇選夢淵製 築齋範憲製夢憲獵願鹽 (網獵衊遞網廠繭簾蓋淵, 窪膚築齋壓餘蓋遞齋鹽 ~ 鹽餘鹹選製醖餘構餘蓋) 更多 | - | 2015-08-25 | ||
(Amlodipine Besylate (AMLb)) | 艱構鏇簾遞夢淵願鑰築(遞鹽構築齋簾鹹積窪選) = 餘衊觸積築艱襯衊艱製 築齋範憲製夢憲獵願鹽 (網獵衊遞網廠繭簾蓋淵, 繭艱遞廠廠餘選繭蓋獵 ~ 齋壓積築廠糧築壓鑰鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用